Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Ratain

Showing results (21-30 of 366) with videos related to

Pageof 37
Sort By:
Clinical Advances in Hematology & Oncology : H&O|October 31, 2014
Incorporating biomarkers into drug labelingMark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudyMark J Ratain
Journal of the National Comprehensive Cancer Network : JNCCN|August 16, 2024
Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug AccessAustin Wesevich, Mark J Ratain
Pharmacogenomics|December 23, 2006
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotypingFederico Innocenti, Mark J Ratain
Journal of the National Cancer Institute|September 28, 2011
Oncology micro-cap stocks: caveat emptor!Adam Feuerstein, Mark J Ratain
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Dose optimization of sotorasib: Has the burden of proof for the labeled dose been met?Sanjay Popat, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Individualizing dosing of irinotecanMark J Ratain, Federico Innocenti
Clinical Pharmacology and Therapeutics|June 5, 2004
"Irinogenetics" and UGT1A: from genotypes to haplotypesFederico Innocenti, Mark J Ratain
JAMA Oncology|August 31, 2023
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?Austin Wesevich, Mark J Ratain
Clinical Pharmacology and Therapeutics|November 4, 2020
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of OlaratumabApostolos Papachristos, Mark J Ratain
Pageof 37

Showing results (21-30 of 366) with videos related to

Sort By:
Pageof 37
Clinical Advances in Hematology & Oncology : H&O|October 31, 2014
Incorporating biomarkers into drug labelingMark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudyMark J Ratain
Journal of the National Comprehensive Cancer Network : JNCCN|August 16, 2024
Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug AccessAustin Wesevich, Mark J Ratain
Pharmacogenomics|December 23, 2006
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotypingFederico Innocenti, Mark J Ratain
Journal of the National Cancer Institute|September 28, 2011
Oncology micro-cap stocks: caveat emptor!Adam Feuerstein, Mark J Ratain
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Dose optimization of sotorasib: Has the burden of proof for the labeled dose been met?Sanjay Popat, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Individualizing dosing of irinotecanMark J Ratain, Federico Innocenti
Clinical Pharmacology and Therapeutics|June 5, 2004
"Irinogenetics" and UGT1A: from genotypes to haplotypesFederico Innocenti, Mark J Ratain
JAMA Oncology|August 31, 2023
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?Austin Wesevich, Mark J Ratain
Clinical Pharmacology and Therapeutics|November 4, 2020
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of OlaratumabApostolos Papachristos, Mark J Ratain
Pageof 37